Article Text

Download PDFPDF
Loss-of-function mutations in the filaggrin gene: no contribution to disease susceptibility, but to autoantibody formation against citrullinated peptides in early rheumatoid arthritis
  1. U Hüffmeier1,
  2. U Böiers2,
  3. J Lascorz1,
  4. A Reis1,
  5. H Burkhardt2
  1. 1
    Institute of Human Genetics, University Erlangen-Nuremberg, Erlangen, Germany
  2. 2
    Division of Rheumatology, Department of Internal Medicine II, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
  1. Prof.Dr H Burkhardt, Division of Rheumatology, Department of Internal Medicine II, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany; harald.burkhardt{at}


Objectives: Autoantibody formation to citrullinated (pro)filaggrin has proven to be a highly specific serological marker for rheumatoid arthritis (RA). To test the potential relevance of mutations of the filaggrin (FLG) gene for disease susceptibility and elicitation of humoural autoimmunity in RA, a case–control association study of three loss-of-function FLG variants was performed.

Methods: DNA was obtained from 282 patients with early RA (mean disease duration: 6.5 months) and from 376 control individuals. Three loss-of-function variants of the FLG gene (*R501X, *2282del4 and *3702del1) were genotyped.

Results: No significant differences in genotype frequencies were observed between control probands and the population of RA patients. The FLG*3702del1 allele was not identified in any of the patients nor controls, and none of the probands was homozygous or compound heterozygous. In the RA cohort, heterozygous carriers of either of the FLG variants exhibited a significantly elevated prevalence of autoantibodies to citrullinated peptides (CCP-2) (80%) compared to non-carriers (51.9%) (p = 0.018, odds ratio: 3.71 (1.20–11.46)).

Conclusions: The investigated FLG variants do not confer an overall risk for the development of RA. However, loss-of-function mutations in the FLG gene may contribute to the development of humoural autoimmunity, targeting citrullinated determinants in early RA.

View Full Text

Statistics from


  • Funding: Supported by Grants from the German Research Foundation (DFG. Re679/10-4 and Bu548/2-1), Marie Curie Early Research Training Grant (MEST-CT-2004-514483), and from the Interdisciplinary Centre for Clinical Research (IZKF B32/A8) of the University of Erlangen-Nürnberg.

  • Competing interests: None

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.